

# Opioid Overdose and the COVID-19 Pandemic

Geetha Subramaniam, MD DFAPA, DFAACP  
Center for Clinical Trials Network, NIDA




# Disclosure Information

- ◆ Chair: Geetha Subramaniam, MD
  - ◆ Employee of NIH/NIDA
- ◆ Presenter 1: Sandra Comer, MD
  - ◆ Name of Companies: Alkermes, BioXcel, Corbus, GoMedical (NIDA grant), Intra-cellular Therapies (NIDA grant), Lyndra (NIDA grant), and Janssen. *Role: Research funding and/or study medications.*
  - ◆ Name of Companies: Alkermes, Charleston Labs, Clinilabs, Collegium, Epiodyne, Mallinckrodt, Nektar, Opiant, Osmotica, Otsuka, and SunPharma. *Role: Consultant*
- ◆ Presenter 2: David Fiellin, MD
  - ◆ No Disclosures
- ◆ Presenter 3: Andrew Herring, MD
  - ◆ No Disclosures

# Learning Objectives

- ◆ Learn about epidemiological trends in OD deaths during the COVID-19 epidemic
- ◆ Describe the role of Fentanyl in OD deaths; its pharmacology and treatment challenges
- ◆ Describe the impact of COVID-19 on treatment access and delivery of MOUD/naloxone; and policy/regulation changes
- ◆ Learn about the epidemiology of non-fatal OD presenting to EDs; and ED efforts to curb OD mortality rates

# Four Waves of the Drug Overdose Epidemic



Source: The Multiple Cause of Death data are produced by the Division of Vital Statistics, National Center for Health Statistics (NCHS), CDC, US DHHS



# Increased OD Death Rates During COVID-19 Pandemic: 12-mo Ending June 2020 Compared to 12-mo Ending June 2019

	ALL DRUGS	HEROIN	NAT & SEMI - SYNTHETIC	METHADONE	SYNTHETIC OPIOIDS	COCAINE	OTHER PSYCHO-STIMULANTS (mainly meth)
June-19	68,711	14,856	12,148	2,863	33,164	14,894	14,583
June-20	83,335	14,480	12,966	3,195	48,006	19,215	20,318
% Change	<b>21.3%</b>	<b>-2.5%</b>	<b>6.7%</b>	<b>11.6%</b>	<b>44.8%</b>	<b>29.0%</b>	<b>39.3%</b>

Source: NCHS Provisional Drug Overdose Death Counts: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm> (Accessed on 1-18-2021)



#ASAM2021